



REQUEST FOR PROPOSALS: ACCELERATION DRUG DISCOVERY FOR FRONTOTEMPORAL DEGENERATION

Upcoming Deadlines

Must be received by 5:00 pm EST on the deadline date.

Letter of Intent

July 13, 2018

Invited Full Proposal

August 10, 2018

Average Duration

One year with potential for follow-on funding.

Average Award

\$100,000-\$150,000

Eligibility

Funding is open to researchers and clinicians in the U.S. and worldwide working in:

- **Academic** medical centers and universities or non-profits. Industry partnerships are strongly encouraged.
- **Biotechnology companies** that demonstrate a clear need for non-profit funding. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new spinouts are both eligible.

Introduction

Research investigating the pathogenic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. However, there remains a global gap in FTD drug discovery research. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD through this Request for Proposals (RFP).

Funding Priorities

- Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and *in vitro* ADME
- Testing of novel lead compounds, biologics, or repurposed drug candidates in relevant animal models for *in vivo* pharmacokinetics, dose-range finding, target engagement, *in vivo* efficacy, and/or preliminary rodent tolerability studies

For *in vivo* efficacy studies, proposals should:

- Demonstrate blood-brain barrier penetration (if the intended target is in the CNS)
- Justify dosing administration and regimen with *in vivo* PK/PD data
- Include measures of target engagement



Alzheimer's
Drug Discovery
Foundation



The Association for
Frontotemporal Degeneration
FIND HELP • SHARE HOPE

For studies testing repurposed drugs, proposals should:

- Evaluate known side effects of the drug and how well they would be tolerated by the intended FTD patients
- Identify a supplier that will provide sufficient quantities of the drug or compound to complete the study aims
- Demonstrate plans to develop novel intellectual property around the repurposing/repositioning strategy

This RFP does **not** support target identification, target validation, assay development, or high-throughput and high-content screening.

[REVIEW THE APPLICATION INSTRUCTIONS](#)

For program-related inquiries, please contact:

Lauren Friedman, PhD, Director, Scientific Affairs, ADDF

Phone: 212.901.8017

Email: lfriedman@alzdiscovery.org

Nadine Tatton, PhD, Scientific Director, AFTD

Phone: 267.514.7221

Email: ntatton@theaftd.org

For application submission inquiries, please contact:

Grants and Mission-Related Investments Team

Phone: 212.901.8019

Email: grants@alzdiscovery.org

ADDF FUNDING PORTAL

[LOG IN](#) OR
[CREATE ACCOUNT](#)